Company Profile
Profil emiten IDX — keuangan, direksi, komisaris, anak usaha
PT UBC Medical Indonesia Tbk
LABS
Sector: Healthcare
Industry: Healthcare Equipment & Supplies
Sub Sector: Healthcare Equipment & Providers
Sub Industry: Healthcare Supplies & Distributions
Live quote
tidak tersedia
tidak tersedia
Highlight Keuangan (2026 Q2) (In Rp)
EPS
2
ROE
5,41%
ROA
3,80%
Book Value
40
Net Income
4,24 M
Total Sales
95,22 M
Total Assets
223,35 M
DER
0.43x
Struktur Pemegang Saham (>1%)
Free Float Information
Saham tersebar di publik
14,76%
72,39%
3,29%
3,29%
3,29%
Tentang Perusahaan
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Produk & Lini Bisnis
The Company main business activity is in the field of distributing medical devices. Wholesale Trade in Laboratory Equipment, Pharmaceutical Equipment and Medical Equipment for Humans, which includes wholesale trade in laboratory equipment, pharmaceutical equipment and medical equipment for humans, with the Standard Classification Code for Indonesian Business Fields (KBLI) 46691.
Dewan Direksi
FY
FX. Yoshua Raintjung
President Director
MA
Marcela Angelin
Director
Dewan Komisaris
NT
Nathan Tirtana
President Commissioner
S
Suyanto
Independent Commissioner
Anak Usaha & Afiliasi
| Nama | Domisili | % |
|---|---|---|
| PT. Esora Medika Indonesia Pharmaceutical industry, chemical products and traditional medicine |
East Jakarta | 99.99% |
| PT. Elion Medika Indonesia Trading, health activity |
South Jakarta | 0.00% |
Trend Keuangan (5 periode terakhir)
— hover bar untuk detail
Total Sales
Net Income (+)
Net Income (-)
2025 Q2
EPS 4
ROE 9,68%
2025 Q3
EPS 4
ROE 10,58%
2025 Q4
EPS 3
ROE 8,86%
2026 Q1
EPS 0
ROE 1,07%
2026 Q2
EPS 2
ROE 5,41%
Laporan Keuangan Historis (5 Periode Terakhir) (In Rp)
| Periode | Total Sales | Net Income | Total Assets | Total Equity | EPS | ROE | DER |
|---|---|---|---|---|---|---|---|
| 2026 Q2 | 95,22 M | 4,24 M | 223,35 M | 156,70 M | 2 | 5,41% | 0.43x |
| 2026 Q1 | 40,02 M | 409,63 Jt | 218,61 M | 152,87 M | 0 | 1,07% | 0.43x |
| 2025 Q4 | 199,30 M | 13,51 M | 228,19 M | 152,46 M | 3 | 8,86% | 0.50x |
| 2025 Q3 | 135,44 M | 11,96 M | 217,49 M | 150,72 M | 4 | 10,58% | 0.44x |
| 2025 Q2 | 86,70 M | 7,06 M | 209,16 M | 145,81 M | 4 | 9,68% | 0.43x |
History Harga Penutupan & Book Value
| Tahun | Qrt | Close Price (Rp) | Book Value (Rp) | ROA |
|---|---|---|---|---|
| 2026 | 2 | 135 | 40 | 3,80% |
| 2026 | 1 | 157 | 39 | 0,75% |
| 2025 | 4 | 137 | 39 | 5,92% |
| 2025 | 3 | 141 | 38 | 7,33% |
| 2025 | 2 | 136 | 37 | 6,75% |
Data diperbarui pada: 2026-05-12 11:03:56